Loading…
Mural Oncology Plc, A Clinical-Stage Company, Is Dedicated To Discovering And Advancing Immune-Based Therapies For Individuals Battling Cancer. Its Primary Drug Candidate, Nemvaleukin Alfa, Is Currently Under Investigation As A Standalone Agent For Mucosal Melanoma And In Partnership With Pembrolizumab For Platinum-Resistant Ovarian Cancer. Additionally, The Company Is Progressing Projects Centered On Modified Interleukin-18 And Tumor-Specific Interleukin-12. Incorporated In 2017, Mural Oncology Maintains Its Headquarters In Dublin, Ireland. By November 15, 2023, The Company Had Transitioned From Being A Subsidiary Of Alkermes Plc.